Research Article
BibTex RIS Cite

C-reactive protein to albumin ratio as a prognostic marker in community-acquired pneumonia mortality

Year 2025, Volume: 16 Issue: 1, 180 - 185, 25.03.2025
https://doi.org/10.18663/tjcl.1640626

Abstract

Aim: This study aimed to evaluate the prognostic value of the C-reactive protein-to-albumin ratio (CAR) in predicting 30-day mortality among patients diagnosed with community-acquired pneumonia (CAP) presenting to the emergency department (ED).
Material and Methods: A retrospective study was conducted on 312 patients diagnosed with CAP who presented to the ED of a tertiary care hospital between January 1, 2022, and January 1, 2024. Demographic, clinical, and laboratory data were collected, including C-reactive protein (CRP) and albumin levels. CAR was calculated by dividing CRP levels (mg/dL) by albumin levels (g/L). The primary outcome was 30-day mortality. The prognostic performance of CAR was evaluated using receiver operating characteristic (ROC) curve analysis.
Results: Of the 312 patients included, 87 (27.9%) died within 30 days. The deceased group had significantly higher CAR values compared to survivors (1.18 ± 0.62 vs. 0.52 ± 0.25, p < 0.001). CAR demonstrated excellent discriminatory power for predicting 30-day mortality, with an area under the curve (AUC) of 0.837 (95% CI: 0.791–0.876, p < 0.001). At a cut-off value of >0.77, CAR achieved a sensitivity of 75.9% and a specificity of 86.7%. Deceased patients also exhibited significantly lower systolic and diastolic blood pressures, oxygen saturation, and albumin levels, along with higher CRP levels and respiratory rates. Comorbidities such as stroke and congestive heart failure were more prevalent in the deceased group compared to survivors.
Conclusion: The C-reactive protein-to-albumin ratio is a reliable prognostic marker for predicting 30-day mortality in CAP patients presenting to the ED. Its ease of calculation and strong discriminatory power make CAR a valuable tool for risk stratification and clinical decision-making. Prospective studies are warranted to confirm these findings in diverse populations.

References

  • Cilloniz C, Ward L, Mogensen ML, et al. Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia: Development and Validation Study. Chest. 2023;163(1):77-88. 10.1016/j.chest.2022.07.005
  • Eshwara VK, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: An update. Indian J Med Res. 2020;151(4):287-302. 10.4103/ijmr.IJMR_1678_19
  • Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. Lancet. 2021;398(10303):906-919. 10.1016/S0140-6736(21)00630-9
  • See XY, Wang TH, Chang YC, et al. Impact of different corticosteroids on severe community-acquired pneumonia: a systematic review and meta-analysis. BMJ Open Respir Res. 2024;11(1):e002141. 10.1136/bmjresp-2023-002141
  • Rothberg MB. Community-Acquired Pneumonia. Ann Intern Med. 2022;175(4):ITC49-ITC64. 10.7326/AITC202204190
  • Ak R, Doğanay F, Yilmaz E. Comparison of C-reactive protein and C-reactive protein-to-albumin ratio in predicting mortality among geriatric coronavirus disease 2019 patients. Rev Assoc Med Bras (1992). 2022;68(1):82-86. 10.1590/1806-9282.20210811
  • Erstad BL. Albumin disposition in critically Ill patients. J Clin Pharm Ther. 2018;43(5):746-751. 10.1111/jcpt.12742
  • Liu Y, Gao Y, Liang B, Liang Z. The prognostic value of C-reactive protein to albumin ratio in patients with sepsis: a systematic review and meta-analysis. Aging Male. 2023;26(1):2261540. 10.1080/13685538.2023.2261540
  • Zhu M, Ma Z, Zhang X, et al. C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis. BMC Med. 2022;20(1):301. 10.1186/s12916-022-02506-x
  • Yang X, Yang X, Yang J, Wen X, Wu S, Cui L. High levels of high-sensitivity C reactive protein to albumin ratio can increase the risk of cardiovascular disease. J Epidemiol Community Health. 2023;77(11):721-727. 10.1136/jech-2023-220760
  • Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. 10.1164/rccm.201908-1581ST
  • Cillóniz C, Dominedò C, Pericàs JM, Rodriguez-Hurtado D, Torres A. Community-acquired pneumonia in critically ill very old patients: a growing problem. Eur Respir Rev. 2020;29(155):190126. 10.1183/16000617.0126-2019
  • Weir DL, Majumdar SR, McAlister FA, et al. The impact of multimorbidity on short-term events in patients with community-acquired pneumonia: prospective cohort study. Clin Microbiol Infect 2015; 21: 264.e7–264.e13. 10.1016/j.cmi.2014.08.016
  • Ramirez JA, Wiemken TL, Peyrani P, et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017;65(11):1806-1812. 10.1093/cid/cix647
  • Umaç GA, Erdoğan A, Can FE. Investigation of oxygen saturation levels in respiratory system diseases in the COVID-19 pandemic. Ann Clin Anal Med. 2023;14(11):986-989. 10.4328/ACAM.21722
  • Rizo-Téllez SA, Sekheri M, Filep JG. C-reactive protein: a target for therapy to reduce inflammation. Front Immunol. 2023;14:1237729. 10.3389/fimmu.2023.1237729
  • Shaikh F, Shaikh FH, Chandio SA. Frequency of Hypoalbuminemia and In-Hospital Mortality in Acute Ischemic Stroke Patients Presenting at a Tertiary Care Hospital, Hyderabad. Cureus. 2021;13(4):e14256. 10.7759/cureus.14256
  • Gyawali P, Shrestha H, Pant V, Risal P, Gautam S. C-reactive Protein to Albumin Ratio among Patients Admitted to Intensive Care Unit of a Tertiary Care Hospital: A Descriptive Crosssectional Study. JNMA J Nepal Med Assoc. 2021;59(244):1247-51. 10.31729/jnma.7047
  • Li Y, Li H, Song C, et al. Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio. Dis Markers. 2021;2021:6304189. 10.1155/2021/6304189
  • Jiang X, Zhang C, Pan Y, Cheng X, Zhang W. Effects of C-reactive protein trajectories of critically ill patients with sepsis on in-hospital mortality rate. Sci Rep. 2023;13(1):15223. 10.1038/s41598-023-42352-2
  • Luo B, Sun M, Huo X, Wang Y. Two new inflammatory markers related to the CURB-65 score for disease severity in patients with community-acquired pneumonia: The hypersensitive C-reactive protein to albumin ratio and fibrinogen to albumin ratio. Open Life Sci. 2021;16(1):84-91. 10.1515/biol-2021-0011
  • Özdemir S, Akça HŞ, Algın A, Eroğlu SE. Can C-reactive protein-to-albumin ratio be a predictor of short-term mortality in community-acquired pneumonia? Ann Clin Anal Med. 2021;12(9):1043-8. 10.4328/ACAM.20576.
  • Lee JH, Kim J, Kim K, et al. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J Crit Care. 2011;26(3):287-94. 10.1016/j.jcrc.2010.10.007

Toplum kökenli pnömonide mortaliteyi öngören bir belirteç olarak C-reaktif protein/albumin oranı

Year 2025, Volume: 16 Issue: 1, 180 - 185, 25.03.2025
https://doi.org/10.18663/tjcl.1640626

Abstract

Amaç: Bu çalışma, acil servise (AS) başvuran toplum kökenli pnömoni (TKP) tanısı almış hastalarda C-reaktif protein/albumin oranının (CAR) 30 günlük mortaliteyi öngörmedeki prognostik değerini değerlendirmeyi amaçlamaktadır.
Gereç ve Yöntemler: Bu retrospektif çalışma, 1 Ocak 2022 ile 1 Ocak 2024 tarihleri arasında üçüncü basamak bir hastanenin AS’ine başvuran ve TKP tanısı konulan 312 hastayı içermektedir. Demografik, klinik ve laboratuvar verileri, C-reaktif protein (CRP) ve albumin düzeyleri dahil olmak üzere toplanmıştır. CAR, CRP düzeyinin (mg/dL) albumin düzeyine (g/L) bölünmesiyle hesaplanmıştır. Birincil sonuç, 30 günlük mortalite olarak belirlenmiştir. CAR'ın prognostik performansı, ROC eğrisi (receiver operating characteristic) analizi kullanılarak değerlendirilmiştir.
Bulgular: Çalışmaya dahil edilen 312 hastanın 87’si (%27,9) 30 gün içinde hayatını kaybetmiştir. Hayatta kalamayan hastalar, sağ kalanlara kıyasla anlamlı derecede yüksek CAR değerlerine sahipti (1,18 ± 0,62'ye karşı 0,52 ± 0,25, p < 0,001). CAR, 30 günlük mortaliteyi öngörmede mükemmel ayırt edici güce sahipti (Eğri altındaki alan (AUC): 0,837, %95 GA: 0,791–0,876, p < 0,001). >0,77 eşik değeri kullanıldığında, CAR %75,9 duyarlılık ve %86,7 özgüllük gösterdi.Hayatta kalamayan hastalar ayrıca daha düşük sistolik ve diyastolik kan basıncına, oksijen satürasyonuna ve albumin düzeylerine sahipken, daha yüksek CRP düzeyleri ve solunum hızları gösterdi. Ayrıca, inme ve konjestif kalp yetmezliği gibi komorbiditeler hayatta kalamayan hastalarda sağ kalanlara kıyasla daha yaygındı.
Sonuç: C-reaktif protein/albumin oranı (CAR), TKP hastalarında 30 günlük mortaliteyi öngörmede güvenilir bir prognostik belirteçtir. Kolay hesaplanabilirliği ve güçlü ayırt edici gücü nedeniyle, CAR risk sınıflandırması ve klinik karar verme süreçlerinde değerli bir araç olabilir. Bu bulguların farklı popülasyonlarda doğrulanması için prospektif çalışmalara ihtiyaç duyulmaktadır.

References

  • Cilloniz C, Ward L, Mogensen ML, et al. Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia: Development and Validation Study. Chest. 2023;163(1):77-88. 10.1016/j.chest.2022.07.005
  • Eshwara VK, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: An update. Indian J Med Res. 2020;151(4):287-302. 10.4103/ijmr.IJMR_1678_19
  • Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. Lancet. 2021;398(10303):906-919. 10.1016/S0140-6736(21)00630-9
  • See XY, Wang TH, Chang YC, et al. Impact of different corticosteroids on severe community-acquired pneumonia: a systematic review and meta-analysis. BMJ Open Respir Res. 2024;11(1):e002141. 10.1136/bmjresp-2023-002141
  • Rothberg MB. Community-Acquired Pneumonia. Ann Intern Med. 2022;175(4):ITC49-ITC64. 10.7326/AITC202204190
  • Ak R, Doğanay F, Yilmaz E. Comparison of C-reactive protein and C-reactive protein-to-albumin ratio in predicting mortality among geriatric coronavirus disease 2019 patients. Rev Assoc Med Bras (1992). 2022;68(1):82-86. 10.1590/1806-9282.20210811
  • Erstad BL. Albumin disposition in critically Ill patients. J Clin Pharm Ther. 2018;43(5):746-751. 10.1111/jcpt.12742
  • Liu Y, Gao Y, Liang B, Liang Z. The prognostic value of C-reactive protein to albumin ratio in patients with sepsis: a systematic review and meta-analysis. Aging Male. 2023;26(1):2261540. 10.1080/13685538.2023.2261540
  • Zhu M, Ma Z, Zhang X, et al. C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis. BMC Med. 2022;20(1):301. 10.1186/s12916-022-02506-x
  • Yang X, Yang X, Yang J, Wen X, Wu S, Cui L. High levels of high-sensitivity C reactive protein to albumin ratio can increase the risk of cardiovascular disease. J Epidemiol Community Health. 2023;77(11):721-727. 10.1136/jech-2023-220760
  • Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. 10.1164/rccm.201908-1581ST
  • Cillóniz C, Dominedò C, Pericàs JM, Rodriguez-Hurtado D, Torres A. Community-acquired pneumonia in critically ill very old patients: a growing problem. Eur Respir Rev. 2020;29(155):190126. 10.1183/16000617.0126-2019
  • Weir DL, Majumdar SR, McAlister FA, et al. The impact of multimorbidity on short-term events in patients with community-acquired pneumonia: prospective cohort study. Clin Microbiol Infect 2015; 21: 264.e7–264.e13. 10.1016/j.cmi.2014.08.016
  • Ramirez JA, Wiemken TL, Peyrani P, et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017;65(11):1806-1812. 10.1093/cid/cix647
  • Umaç GA, Erdoğan A, Can FE. Investigation of oxygen saturation levels in respiratory system diseases in the COVID-19 pandemic. Ann Clin Anal Med. 2023;14(11):986-989. 10.4328/ACAM.21722
  • Rizo-Téllez SA, Sekheri M, Filep JG. C-reactive protein: a target for therapy to reduce inflammation. Front Immunol. 2023;14:1237729. 10.3389/fimmu.2023.1237729
  • Shaikh F, Shaikh FH, Chandio SA. Frequency of Hypoalbuminemia and In-Hospital Mortality in Acute Ischemic Stroke Patients Presenting at a Tertiary Care Hospital, Hyderabad. Cureus. 2021;13(4):e14256. 10.7759/cureus.14256
  • Gyawali P, Shrestha H, Pant V, Risal P, Gautam S. C-reactive Protein to Albumin Ratio among Patients Admitted to Intensive Care Unit of a Tertiary Care Hospital: A Descriptive Crosssectional Study. JNMA J Nepal Med Assoc. 2021;59(244):1247-51. 10.31729/jnma.7047
  • Li Y, Li H, Song C, et al. Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio. Dis Markers. 2021;2021:6304189. 10.1155/2021/6304189
  • Jiang X, Zhang C, Pan Y, Cheng X, Zhang W. Effects of C-reactive protein trajectories of critically ill patients with sepsis on in-hospital mortality rate. Sci Rep. 2023;13(1):15223. 10.1038/s41598-023-42352-2
  • Luo B, Sun M, Huo X, Wang Y. Two new inflammatory markers related to the CURB-65 score for disease severity in patients with community-acquired pneumonia: The hypersensitive C-reactive protein to albumin ratio and fibrinogen to albumin ratio. Open Life Sci. 2021;16(1):84-91. 10.1515/biol-2021-0011
  • Özdemir S, Akça HŞ, Algın A, Eroğlu SE. Can C-reactive protein-to-albumin ratio be a predictor of short-term mortality in community-acquired pneumonia? Ann Clin Anal Med. 2021;12(9):1043-8. 10.4328/ACAM.20576.
  • Lee JH, Kim J, Kim K, et al. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J Crit Care. 2011;26(3):287-94. 10.1016/j.jcrc.2010.10.007
There are 23 citations in total.

Details

Primary Language English
Subjects Emergency Medicine
Journal Section Research Article
Authors

İzzet Ustaalioğlu 0000-0001-9703-8344

Özge Kibici 0000-0002-1480-2018

Publication Date March 25, 2025
Submission Date February 15, 2025
Acceptance Date March 20, 2025
Published in Issue Year 2025 Volume: 16 Issue: 1

Cite

APA Ustaalioğlu, İ., & Kibici, Ö. (2025). C-reactive protein to albumin ratio as a prognostic marker in community-acquired pneumonia mortality. Turkish Journal of Clinics and Laboratory, 16(1), 180-185. https://doi.org/10.18663/tjcl.1640626
AMA Ustaalioğlu İ, Kibici Ö. C-reactive protein to albumin ratio as a prognostic marker in community-acquired pneumonia mortality. TJCL. March 2025;16(1):180-185. doi:10.18663/tjcl.1640626
Chicago Ustaalioğlu, İzzet, and Özge Kibici. “C-Reactive Protein to Albumin Ratio As a Prognostic Marker in Community-Acquired Pneumonia Mortality”. Turkish Journal of Clinics and Laboratory 16, no. 1 (March 2025): 180-85. https://doi.org/10.18663/tjcl.1640626.
EndNote Ustaalioğlu İ, Kibici Ö (March 1, 2025) C-reactive protein to albumin ratio as a prognostic marker in community-acquired pneumonia mortality. Turkish Journal of Clinics and Laboratory 16 1 180–185.
IEEE İ. Ustaalioğlu and Ö. Kibici, “C-reactive protein to albumin ratio as a prognostic marker in community-acquired pneumonia mortality”, TJCL, vol. 16, no. 1, pp. 180–185, 2025, doi: 10.18663/tjcl.1640626.
ISNAD Ustaalioğlu, İzzet - Kibici, Özge. “C-Reactive Protein to Albumin Ratio As a Prognostic Marker in Community-Acquired Pneumonia Mortality”. Turkish Journal of Clinics and Laboratory 16/1 (March 2025), 180-185. https://doi.org/10.18663/tjcl.1640626.
JAMA Ustaalioğlu İ, Kibici Ö. C-reactive protein to albumin ratio as a prognostic marker in community-acquired pneumonia mortality. TJCL. 2025;16:180–185.
MLA Ustaalioğlu, İzzet and Özge Kibici. “C-Reactive Protein to Albumin Ratio As a Prognostic Marker in Community-Acquired Pneumonia Mortality”. Turkish Journal of Clinics and Laboratory, vol. 16, no. 1, 2025, pp. 180-5, doi:10.18663/tjcl.1640626.
Vancouver Ustaalioğlu İ, Kibici Ö. C-reactive protein to albumin ratio as a prognostic marker in community-acquired pneumonia mortality. TJCL. 2025;16(1):180-5.


e-ISSN: 2149-8296

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.